GW 0742Cat. No. 2229 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: [4-[[[2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid |
Biological Activity
Potent and highly selective PPARδ agonist. EC50 values are 0.001, 1.1 and 2 μM for transactivation of human PPARδ, -α, and -γ receptors respectively. Neuroprotective in rat cerebellar granule neuronal cultures after brief (12-hour) exposure but exhibits inherent toxicity after prolonged (48-hour) incubation. Increases rate of fatty acid oxidation and protects against ischemia/reperfusion injury in neonatal and adult cardiomyocytes.Licensing Information
Sold for research purposes under agreement from GlaxoSmithKlineCertificate of Analysis / Safety Data Sheet
References
Sznaidman et al (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) - Synthesis and biological activity. Bioorg.Med.Chem.Lett. 13 1517. PMID: 12699745.
Smith et al (2004) Effect of the peroxisome proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons. J.Neurosci.Res. 77 240. PMID: 15211590.
Yue et al (2008) In vivo activation of peroxisome proliferator-activayed receptor-δ protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J.Pharm.Exp.Ther. 325 466.
If you know of a relevant citation for this product please let us know.
Keywords: GW 0742, supplier, selective, potent, PPARδ, PPARdelta, agonists, Peroxisome, Proliferator-activating, Receptors, GW0742, GlaxoSmithKline, GSK
Quick Order
Find multiple products by catalog number
New Products in this Area
High affinity PPARγ ligand; blocks Cdk5-dependent PPARγ phosphorylation
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.



